<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572078</url>
  </required_header>
  <id_info>
    <org_study_id>0706-05 IUCRO-0171</org_study_id>
    <nct_id>NCT00572078</nct_id>
  </id_info>
  <brief_title>Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors</brief_title>
  <official_title>Phase I Dose-Escalation Drug-Interaction Study of Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Safi Shahda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability and describe the maximum&#xD;
      tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with&#xD;
      bevacizumab and paclitaxel for patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2008</start_date>
  <completion_date type="Actual">September 14, 2014</completion_date>
  <primary_completion_date type="Actual">January 4, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.</measure>
    <time_frame>baseline through end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of paclitaxel and sorafenib alone and in combination</measure>
    <time_frame>baseline through end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacodynamic changes a)in tumor vascular parameters and b)in plasma VEGF and soluble VEGF receptor levels, and correlate with clinical outcomes and sorafenib pharmacokinetic (PK) profile.</measure>
    <time_frame>baseline through end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate variants in genes of paclitaxel drug-metabolism and drug-transporters P glycoprotein and correlate with PK profile for paclitaxel and with clinical outcomes</measure>
    <time_frame>baseline through end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>SOLID TUMORS</condition>
  <arm_group>
    <arm_group_label>Sorafenib, Bevacizumab &amp; Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID</description>
    <arm_group_label>Sorafenib, Bevacizumab &amp; Paclitaxel</arm_group_label>
    <other_name>Bay 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of a solid tumor with evidence of residual,&#xD;
             recurrent, or metastatic disease. Patients must be incurable by surgical or other&#xD;
             standard available therapy&#xD;
&#xD;
          -  Measurable or evaluable disease; tumor size of ≥ 2 cm on CT scan&#xD;
&#xD;
          -  Patients may have received prior standard taxane therapy or anti-VEGF therapy, but may&#xD;
             not have progressed on both therapies. Progression on one type therapy (either taxane&#xD;
             or anti-VEGF) is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of central nervous system (CNS) disease (i.e., primary brain&#xD;
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis).&#xD;
&#xD;
          -  Prior chemotherapy ≤ 3 weeks prior to registration. Patients must have recovered from&#xD;
             all therapy-related toxicities&#xD;
&#xD;
          -  Prior biologic or immunotherapy ≤ 3 weeks prior to registration. Patients must have&#xD;
             recovered from all therapy-related toxicities&#xD;
&#xD;
          -  Prior full pelvic field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks&#xD;
             prior to randomization. Patients must have recovered to less than or equal to grade 1&#xD;
             from all therapy-related toxicities except alopecia. The site of previous radiotherapy&#xD;
             should have evidence of progressive disease if this is the only site of evaluable&#xD;
             disease&#xD;
&#xD;
          -  Major surgery (i.e., laparotomy) ≤ 4 weeks prior to randomization or anticipation of&#xD;
             need for major surgical procedure during the course of the study&#xD;
&#xD;
          -  Minor surgery ≤ 2 weeks prior to randomization. Insertion of a vascular access device&#xD;
             is not considered major or minor surgery in this regard. Patients must have recovered&#xD;
             from all surgery-related toxicities&#xD;
&#xD;
          -  Peripheral neuropathy with functional impairment ≥ Common Terminology Criteria (CTC)&#xD;
             grade 2 neuropathy, regardless of causality&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled cardiac, vascular or infectious conditions (as&#xD;
             described in the protocol) which could compromise participation in the study&#xD;
&#xD;
          -  Patients at risk of QT prolongation such as patients with congenital long QT syndrome&#xD;
             or with long corrected QT (QTc) at baseline (i.e. QTc greater than 450 msec in males,&#xD;
             and greater than 470 msec in females) will be excluded&#xD;
&#xD;
          -  Lung carcinoma of squamous cell histology (mixed tumors will be categorized by the&#xD;
             predominant cell type unless small cell elements are present, in which case the&#xD;
             patient is ineligible; sputum cytology alone is not acceptable).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safi G Shahda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Safi Shahda</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

